Use of interleukin 10 mrna transfected macrophages in anti-inflammatory therapies

Abstract

The present invention relates to the field of cell-based therapeutics. Specifically, the invention is concerned with a composition comprising a macrophage overexpressing interleukin 10 (IL-10) from transfected IL-10 encoding mRNA for use as a medicament. Moreover, a method for manufacturing a medicament for treating and/or preventing inflammation or a disease or disorder associated therewith comprising the steps of obtaining a macrophage from a sample of said subject, transfecting mRNA encoding IL-10 into said macrophage, and formulating said macrophage in a composition suitable for administration to the said subject, whereby the medicament is manufactured. Finally, a kit is provided for manufacturing such a medicament.

1 .- 10 . (canceled) 
     
     
         11 . A pharmaceutical composition comprising a macrophage overexpressing interleukin 10 (IL-10) from transfected IL-10 encoding mRNA. 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein the macrophage further expresses a polypeptide selected from the group consisting of TGF-β, CXCR-4, and CCR2. 
     
     
         13 . The pharmaceutical composition of  claim 11 , wherein the pharmaceutical composition is useful for treating and/or preventing inflammation or a disease or disorder associated therewith. 
     
     
         14 . The pharmaceutical composition of  claim 11 , wherein the macrophage is obtained by a method comprising the steps of:
 (a) obtaining a macrophage from a sample of a subject; and   (b) transfecting mRNA encoding IL-10 into the macrophage.   
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the pharmaceutical composition is for administration to the subject from which the macrophage was derived. 
     
     
         16 . The pharmaceutical composition of  claim 14 , wherein the subject is a human. 
     
     
         17 . The pharmaceutical composition of  claim 14 , wherein the macrophage is a peritoneal macrophage. 
     
     
         18 . The pharmaceutical composition of  claim 11 , wherein the macrophage expresses IL-10 at least about 2-fold, at least about 4-fold, at least about 6-fold or at least about 7-fold higher than a macrophage which has not been transfected by the IL-10 encoding mRNA. 
     
     
         19 . The pharmaceutical composition of  claim 11 , wherein the pharmaceutical composition treats or alleviates a disease or disorder selected from the group consisting of myocarditis, autoimmune diseases, rheumatoid disease, rheumatoid arthritis, and multiple sclerosis. 
     
     
         20 . The pharmaceutical composition of  claim 19 , wherein the myocarditis is autoimmune myocarditis. 
     
     
         21 . The pharmaceutical composition of  claim 11 , wherein the pharmaceutical composition treats or alleviates local inflammation. 
     
     
         22 . The pharmaceutical composition of  claim 21 , wherein the local inflammation is associated with myocarditis, autoimmune disease, rheumatoid disease, rheumatoid arthritis, or multiple sclerosis. 
     
     
         23 . The pharmaceutical composition of  claim 11 , wherein the pharmaceutical composition is formulated for intravenous administration.